Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$160M Buy
1,200,600
+874,300
+268% +$99M 0.02% 665
2026
Q1
$36.3M Buy
326,300
+125,800
+63% +$14.9M 0.01% 1664
2025
Q4
$27M Buy
200,500
+190,600
+1,925% +$20.8M ﹤0.01% 2025
2025
Q3
$841K Buy
+9,900
New +$607K ﹤0.01% 7924

Other funds holding ABVX

Citadel Advisors's ABVX Position: Q2 2026 in Review

Citadel Advisors increased its Abivax (ABVX) stake by 164% in Q2 2026, buying an estimated $101M and bringing the position to 1,438,352 shares worth $192M. The position accounts for 0.02% of the portfolio, ranked #578.

Citadel Advisors first reported a position in ABVX in Q4 2023 and has held it in 11 quarters since. 303 funds tracked by Wall St. Rank hold ABVX as of Q2 2026.

  • Citadel Advisors held 1,438,352 shares of Abivax worth $192M as of Q2 2026.
  • Citadel Advisors bought 894,014 Abivax shares in Q2 2026, an estimated $101M.
  • Abivax made up 0.02% of Citadel Advisors's portfolio in Q2 2026, its #578 holding.
  • Citadel Advisors first reported a position in Abivax in Q4 2023 and has held it in 11 quarters since.
  • 303 funds tracked by Wall St. Rank held Abivax as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.